Evidence map›Paper›PMID 42886279›Full record

ArticleMikrochimica acta2026

Capillary-integrated chiral gold nanocrystals for label-free SERS detection of serum amyloid-β 1-42 in Alzheimer's disease rats.

Yangfan Zhou, Huaiwu Fu, Kaiyong Chen, Yixuan Jiang, Zixun Wang, Weixing Wu, Xiaowei Cao

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yangfan Zhou *School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou, 225001, PR China.
Huaiwu Fu *Department of Emergency, Guanyun County People's Hospital, 222200, Lianyungang, P. R. China.
Kaiyong ChenDepartment of Laboratory Medicine, Guanyun County People's Hospital, 222200, Lianyungang, P. R. China.
Yixuan JiangThe First School of Clinical Medicine, Faculty of Medicine, Yangzhou University, 225003, Yangzhou, PR China.
Zixun WangThe First School of Clinical Medicine, Faculty of Medicine, Yangzhou University, 225003, Yangzhou, PR China.
Weixing WuDepartment of Emergency, Guanyun County People's Hospital, 222200, Lianyungang, P. R. China. 82718323@qq.com.
Xiaowei CaoSchool of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, 225009, Yangzhou, PR China. cxw19861121@163.com.

Funding

the Major Programs of Natural Science Foundation of higher education in Jiangsu Province 19KJA480003the National Natural Science Foundation of China 81403232the Natural Science Foundation of Jiangsu Province No. BK20171290
6 · The paper itself

Abstract

Chiral plasmonics was integrated with surface-enhanced Raman scattering (SERS) technology to develop a high-performance chiral SERS sensor with promising applications for the early identification and ultrasensitive detection of Alzheimer's disease. The sensor utilizes the self-assembly of chiral gold nanocrystals (CG NCs) on the inner wall of a capillary, introducing a surface-enhanced Raman scattering chiral anisotropy (SERS-ChA) effect. Consequently, a label-free chiral SERS sensor ‌is‌ constructed. In the presence of the target analyte Amyloid-β 1-42 (Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesGoldMetal NanoparticlesPeptide FragmentsSpectrum Analysis, RamanAnimalsLimit of DetectionRatsStereoisomerismAmyloid beta-Peptidesamyloid beta-protein (1-42)GoldPeptide FragmentsAlzheimer's diseaseAβ1−42Chiral gold nanocrystalsSurface-enhanced Raman scattering

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.